Issued Feb. 26 by the U.S. Patent and Trademark Office

U.S. Class: 435-6Patent Number: 4,996,144Assignee: Calgene Inc.Claims/Description: 7 claims for a method to detect a nucleicacidsequence in a sample containing fewer than 500 cells.

U.S. Class: 435-7.23Patent Number: 4,996,145Assignee: Oncotech Inc.Claims/Description: 20 claims for an in vitro method tomeasure the ability of an immune mediated drug to kill tumors

U.S. Class: 435-172.3Patent Number: 4,996,151Assignee: New England Biolabs Inc.Claims/Description: 10 claims for a DNA encoding the EagIrestriction endonuclease.

U.S. Class: 435-172.3Patent Number: 4,996,152Assignee: U.S. Secretary of AgricultureClaims/Description: 12 claims for avian herpes virus eucaryoticexpression vectors.

U.S. Class: 435-252.3Patent Number: 4,996,155Assignee: Mycogen Corp.Claims/Description: 23 claims for a Bacillus thuringiensis geneencoding a beetle toxin.

U.S. Class: 514-21Patent Number: 4,996, 194Assignee: Yeda Research and Development Co. Ltd., Rehovot,IsraelClaims/Description: 34 claims for the use of pressure-treated T-cells to treat autoimmune diseases.

U.S. Class: 530-395Patent Number: 4,996,297Assignee: Zonagen Inc.Claims/Description: 6 claims for recombinant rabbit zonapellucida polypeptides.

(c) 1997 American Health Consultants. All rights reserved.

No Comments